Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3HER2-positive Solid Tumor 1Esophagogastric Cancer 1Breast Cancer Metastases 1

Interventions

Cyclophosphamide 361Trastuzumab 352Paclitaxel 304Docetaxel 272Capecitabine 222Letrozole 221Carboplatin 185Doxorubicin 181Tamoxifen 157Radiotherapy 154Epirubicin 145Fulvestrant 143Anastrozole 139Surveys and Questionnaires 133Exercise 128pertuzumab 113Vinorelbine 110Blood Specimen Collection 109exemestane 106palbociclib 104Bevacizumab 104pembrolizumab 98Magnetic Resonance Spectroscopy 97Albumin-Bound Paclitaxel 87Gemcitabine 84Drug Therapy 83Lapatinib 78130-nm albumin-bound paclitaxel 72Neoadjuvant Therapy 71Cisplatin 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms × zirconium-89-trastuzumab × Clear all
NCT01565200 2025-03-31

ZEPHIR

Jules Bordet Institute

Phase 2 Completed
90 enrolled
Breast

Breast Neoplasms

NCT01832051 2015-11-05

Clinical Value of 89Zr-trastuzumab PET

University Medical Center Groningen

Phase 2 Completed
20 enrolled
Breast

Breast Neoplasms

NCT01081600 2013-05-14

AUY922

University Medical Center Groningen

Completed
7 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡